Drugs / Flu Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT00558649 | May → Sep 2007 | influenza | NanoPass Technologies Ltd | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 0 | NCT01967238 Comparator | Mar 2013 → Mar 2023 | — | Rockefeller University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05568797 Background | Oct 2022 → Feb 2023 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00664339 Comparator | May 2007 → Mar 2008 | heart failure | La Fundacion Favaloro para la Investigacion y la Docencia Medica | Completed | No outcome recorded |
Press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flu Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00664339 ↗ |
| Known as | FLUARIX | “Flu Vaccine (FLUARIX®)” NCT00558649 ↗ |
| Modality | Vaccine | “Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula” NCT00558649 ↗ |
| Route | Intramuscular | “intramuscular influenza vaccination” NCT00664339 ↗ |